- Home
- BEAM vs GTX Comparison
BEAM vs GTX Comparison
Compare BEAM & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- GTX
- Stock Information
- Founded
- BEAM 2017
- GTX 2018
- Country
- BEAM United States
- GTX Switzerland
- Employees
- BEAM N/A
- GTX N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- GTX Auto Parts:O.E.M.
- Sector
- BEAM Health Care
- GTX Consumer Discretionary
- Exchange
- BEAM Nasdaq
- GTX Nasdaq
- Market Cap
- BEAM 1.8B
- GTX 1.9B
- IPO Year
- BEAM 2020
- GTX N/A
- Fundamental
- Price
- BEAM $17.41
- GTX $11.58
- Analyst Decision
- BEAM Strong Buy
- GTX Strong Buy
- Analyst Count
- BEAM 11
- GTX 1
- Target Price
- BEAM $48.90
- GTX $14.00
- AVG Volume (30 Days)
- BEAM 2.2M
- GTX 2.2M
- Earning Date
- BEAM 05-06-2025
- GTX 05-01-2025
- Dividend Yield
- BEAM N/A
- GTX 1.04%
- EPS Growth
- BEAM N/A
- GTX N/A
- EPS
- BEAM N/A
- GTX 1.28
- Revenue
- BEAM $63,578,000.00
- GTX $3,438,000,000.00
- Revenue This Year
- BEAM N/A
- GTX N/A
- Revenue Next Year
- BEAM $6.32
- GTX $7.85
- P/E Ratio
- BEAM N/A
- GTX $9.01
- Revenue Growth
- BEAM N/A
- GTX N/A
- 52 Week Low
- BEAM $13.53
- GTX $7.02
- 52 Week High
- BEAM $35.25
- GTX $10.39
- Technical
- Relative Strength Index (RSI)
- BEAM 43.14
- GTX 81.65
- Support Level
- BEAM $15.51
- GTX $9.01
- Resistance Level
- BEAM $20.90
- GTX $11.35
- Average True Range (ATR)
- BEAM 1.22
- GTX 0.36
- MACD
- BEAM -0.03
- GTX 0.24
- Stochastic Oscillator
- BEAM 35.25
- GTX 96.44
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.